Senti Biosciences, Inc. (SNTI)

Market Cap	27.19M -70.5%
Revenue (ttm)	22,000
Net Income	-61.44M
EPS	-2.73
Shares Out	31.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,420
Open	0.8737
Previous Close	0.8652
Day's Range	0.8580 - 0.8900
52-Week Range	0.7702 - 5.1000
Beta	2.12
Analysts	Strong Buy
Price Target	8.50 (+873.77%)
Earnings Date	May 5, 2026

About SNTI

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood can...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SNTI
• Website: https://www.sentibio.com

Analyst Summary

According to 4 analysts, the average rating for SNTI stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 873.77% from the latest price.

Price Target

$8.5

(873.77% upside)

Analyst Consensus: Strong Buy